abstract |
Pharmaceutical compositions containing a combination of the antiandrogen (5α,17α)-1'-(methylsulfonyl)-1'-H-pregn-20-yno[3,2-c]pyrazol-17-ol (Win 49596, zanoterone) and the 5α-reductase inhibitor (5α,17β)-N-(1,1-dimethylethyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide (finasteride) for treating prostate disease in a male mammal and process for preparation thereof are disclosed. |